BridgeBio and Bayer sign a European licensing deal for acoramidis, a treatment for ATTR-CM, with Bayer receiving exclusive rights and BridgeBio earning royalties and milestone payments.
BridgeBio Pharma and Bayer have announced a European licensing agreement for acoramidis, a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). Bayer will receive exclusive commercialization rights for acoramidis in Europe. BridgeBio will receive royalties beginning in the low-thirties percent, upfront and near-term milestone payments, and potential additional undisclosed sales milestone payments. Acoramidis has received positive results in a global Phase 3 ATTRibute-CM trial and has been accepted by the US FDA and European Medicines Agency for review.
March 04, 2024
12 Articles